Eliem Therapeutics Changes Name to Climb Bio

ELYMDelisted Stock  USD 3.23  0.01  0.31%   
About 61% of Eliem Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Eliem Therapeutics suggests that many traders are alarmed. Eliem Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Eliem Therapeutics. Many technical investors use Eliem Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
By Karen Roman Eliem Therapeutics, Inc. said its new corporate name will be Climb Bio, Inc. and it will start trading at Nasdaq with the ticker symbol CLYM on Oct. 3. This rebranding reflects Climbs laser-focused mission on tackling immune-mediated diseases, it said in a statement. Climbs lead program is budoprutug ,

Read at finance.yahoo.com
Yahoo News
  

Eliem Therapeutics Fundamental Analysis

We analyze Eliem Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eliem Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eliem Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Outstanding

Shares Outstanding Comparative Analysis

Eliem Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Eliem Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eliem Therapeutics stock to make a market-neutral strategy. Peer analysis of Eliem Therapeutics could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics with similar companies.

Peers

Eliem Therapeutics Related Equities

ANEBAnebulo Pharmaceuticals   7.64   
0%
77.0%
ADAGAdagene   6.39   
0%
65.0%
PEPGPepGen   6.37   
0%
64.0%
RZLTRezolute   4.90   
0%
50.0%
STTKShattuck Labs   3.67   
0%
37.0%
PHVSPharvaris   3.29   
0%
33.0%
MOLNMolecular Partners   2.04   
0%
20.0%
CSBRChampions Oncology   0.23   
0%
2.0%
ACRVAcrivon Therapeutics,   0.13   
0%
1.0%
AVTEAerovate Therapeutics   1.50   
15.0%
0%
MNOVMediciNova   3.36   
34.0%
0%
PMVPPmv Pharmaceuticals   4.73   
48.0%
0%
ANTXAN2 Therapeutics   6.25   
63.0%
0%
IPSCCentury Therapeutics   7.74   
78.0%
0%
HCWBHCW Biologics   9.80   
100.0%
0%

Other Consideration for investing in Eliem Stock

If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes